Drug Screening Using Novel IMD in Renal Cell Carcinoma

This research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 19 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against metastatic renal cell carcinoma (RCC). The name of the intervention(s) involved in this study are: * Implantable Microdevice (IMD) * Surgery (excision of tumor) * Drugs used in this study will only include drugs already used as standard of care for the treatment of metastatic renal cell carcinoma (RCC)

Trial Details

NCT ID
NCT05700461
Phase
PHASE1
Sponsor
Oliver Jonas
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Implantable Microdevice (IMD)
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Patients must have the ability to understand and the willingness to sign a written informed consent document.
  • Participants must have confirmed or suspected localized or metastatic renal cell carcinoma, and must be planned for either nephrectomy or metastate…
  • Participants must be 18 years of age or older.
  • Participants must be evaluated by a medical oncologist who will determine the clinically appropriate treatment strategy based on clinical history a…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →